From Wikipedia, the free encyclopedia
FGI-104 Legal status
4-[(7-chloroquinolin-4-yl)amino]-2-(diethylaminomethyl)-6-[4-(hydroxymethyl)-3-methoxyphenyl]phenol
PubChem CID Formula C 28 H 30 Cl N 3 O 3 Molar mass 492.008 g·mol−1 3D model (JSmol )
c4cnc1cc(Cl)ccc1c4Nc(cc2CN(CC)CC)cc(c2O)-c(cc3OC)ccc3CO
FGI-104 is the name of an experimental broad-spectrum antiviral drug , with activity against a range of viruses including Hepatitis B , Hepatitis C , HIV , Ebola virus and Venezuelan equine encephalitis virus . [1]
Mechanism The drug acts by inhibiting the protein TSG101 , which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease .[2]
See also References
^ Kinch, Michael; Yunus, Abdul; Mao, Hanwen; Lear, Calli; Luo, Guangxiang; Murray, Michael; Huang, Zhuhui; Fesseha, Zena; Chen, Hanson; Olinger, Gene; Goldblatt, Michael (2009). "FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection" . Antiviral Research . 82 (2): A39–A40. doi :10.1016/j.antiviral.2009.02.082 . ISSN 0166-3542 . PMC 2776286 ^ Janeba, Zlatko (2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews . 35 (6): 1175–1194. doi :10.1002/med.21355 . ISSN 0198-6325 .
